We analyzed the effect of monensin on 12 cancer-related pathways and found that monensin inhibited the reporter activities for ElK1, Ap1 pathway, and to a lesser extent the Myc/max reporter activity in human colorectal cancer cells. Here, MYC is linked to cancer.